(ARWR) Arrowhead Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US04280A1007
Plozasiran, Olpasiran, Fazirsiran, Zodasiran, Daplusiran
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 94.8% |
| Value at Risk 5%th | 140% |
| Relative Tail Risk | -10.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.55 |
| Alpha | 126.98 |
| CAGR/Max DD | 0.34 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.499 |
| Beta | 1.762 |
| Beta Downside | 1.710 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.86% |
| Mean DD | 35.75% |
| Median DD | 36.85% |
Description: ARWR Arrowhead Pharmaceuticals November 10, 2025
Arrowhead Pharmaceuticals (NASDAQ: ARWR) focuses on RNA-targeted medicines for hard-to-treat diseases. Its late-stage portfolio includes three Phase 3 candidates-Plozasiran (hypertriglyceridemia, dyslipidemia, familial chylomicronemia syndrome), Olpasiran (apo-A reduction) and Fazirsiran (alpha-1 antitrypsin-related liver disease)-plus a suite of Phase 2/1 programs targeting metabolic, hepatic, pulmonary and rare-disease indications. The company leverages a network of collaborations with GlaxoSmithKline, Horizon Therapeutics, Takeda and Amgen to co-develop and commercialize its RNAi platform.
As of the most recent filing, Arrowhead reported a market capitalization of roughly $2.5 billion and cash and equivalents of $300 million, giving it an estimated 12-month runway at current burn rates (~$200 million FY 2023 R&D spend). The biotech sector’s revenue growth is projected at a 10 % CAGR through 2029, driven by expanding demand for gene-silencing therapeutics and favorable reimbursement trends for rare-disease treatments-factors that could amplify ARWR’s upside if its Phase 3 readouts meet primary endpoints.
For a deeper dive into Arrowhead’s valuation metrics and scenario analysis, you might find the research tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (-1.63m TTM) > 0 and > 6% of Revenue (6% = 49.8m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA 64.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 91.04% (prev 2182 %; Δ -2091 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 179.6m > Net Income -1.63m (YES >=105%, WARN >=100%) |
| Net Debt (166.2m) to EBITDA (100.6m) ratio: 1.65 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (135.7m) change vs 12m ago 11.24% (target <= -2.0% for YES) |
| Gross Margin 97.89% (prev 0.0%; Δ 97.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 65.70% (prev 2.38%; Δ 63.32pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.93 (EBITDA TTM 100.6m / Interest Expense TTM 89.4m) >= 6 (WARN >= 3) |
Altman Z'' -1.75
| (A) 0.55 = (Total Current Assets 950.6m - Total Current Liabilities 195.5m) / Total Assets 1.39b |
| (B) -1.17 = Retained Earnings (Balance) -1.63b / Total Assets 1.39b |
| warn (B) unusual magnitude: -1.17 — check mapping/units |
| (C) 0.07 = EBIT TTM 83.1m / Avg Total Assets 1.26b |
| (D) -1.85 = Book Value of Equity -1.63b / Total Liabilities 881.9m |
| Total Rating: -1.75 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 49.34
| 1. Piotroski 5.50pt |
| 2. FCF Yield 2.15% |
| 3. FCF Margin 18.91% |
| 4. Debt/Equity 0.24 |
| 5. Debt/Ebitda 1.65 |
| 6. ROIC - WACC (= -7.34)% |
| 7. RoE -0.38% |
| 8. Rev. Trend -9.36% |
| 9. EPS Trend -3.36% |
What is the price of ARWR shares?
As of December 04, 2025, the stock is trading at USD 65.08 with a total of 4,437,469 shares traded.
Over the past week, the price has changed by +12.76%, over one month by +64.29%, over three months by +134.08% and over the past year by +149.62%.
Over the past week, the price has changed by +12.76%, over one month by +64.29%, over three months by +134.08% and over the past year by +149.62%.
Is ARWR a buy, sell or hold?
Arrowhead Pharmaceuticals has received a consensus analysts rating of 4.13.
Therefore, it is recommended to buy ARWR.
- Strong Buy: 7
- Buy: 3
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ARWR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 55.6 | -14.6% |
| Analysts Target Price | 55.6 | -14.6% |
| ValueRay Target Price | 66.1 | 1.6% |
ARWR Fundamental Data Overview November 29, 2025
Market Cap USD = 7.29b (7.29b USD * 1.0 USD.USD)
P/E Forward = 111.1111
P/S = 8.7844
P/B = 16.8169
P/EG = -1.32
Beta = 1.31
Revenue TTM = 829.4m USD
EBIT TTM = 83.1m USD
EBITDA TTM = 100.6m USD
Long Term Debt = 214.9m USD (from longTermDebt, last quarter)
Short Term Debt = 40.0m USD (from shortLongTermDebt, last quarter)
Debt = 111.4m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 166.2m USD (from netDebt column, last quarter)
Enterprise Value = 7.31b USD (7.29b + Debt 111.4m - CCE 88.7m)
Interest Coverage Ratio = 0.93 (Ebit TTM 83.1m / Interest Expense TTM 89.4m)
FCF Yield = 2.15% (FCF TTM 156.9m / Enterprise Value 7.31b)
FCF Margin = 18.91% (FCF TTM 156.9m / Revenue TTM 829.4m)
Net Margin = -0.20% (Net Income TTM -1.63m / Revenue TTM 829.4m)
Gross Margin = 97.89% ((Revenue TTM 829.4m - Cost of Revenue TTM 17.5m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 77.59%)
Tobins Q-Ratio = 5.28 (Enterprise Value 7.31b / Total Assets 1.39b)
Interest Expense / Debt = 19.47% (Interest Expense 21.7m / Debt 111.4m)
Taxrate = 55.37% (20.0m / 36.1m)
NOPAT = 37.1m (EBIT 83.1m * (1 - 55.37%))
Current Ratio = 4.86 (Total Current Assets 950.6m / Total Current Liabilities 195.5m)
Debt / Equity = 0.24 (Debt 111.4m / totalStockholderEquity, last quarter 466.1m)
Debt / EBITDA = 1.65 (Net Debt 166.2m / EBITDA 100.6m)
Debt / FCF = 1.06 (Net Debt 166.2m / FCF TTM 156.9m)
Total Stockholder Equity = 430.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.12% (Net Income -1.63m / Total Assets 1.39b)
RoE = -0.38% (Net Income TTM -1.63m / Total Stockholder Equity 430.4m)
RoCE = 12.87% (EBIT 83.1m / Capital Employed (Equity 430.4m + L.T.Debt 214.9m))
RoIC = 5.11% (NOPAT 37.1m / Invested Capital 725.7m)
WACC = 12.45% (E(7.29b)/V(7.40b) * Re(12.51%) + D(111.4m)/V(7.40b) * Rd(19.47%) * (1-Tc(0.55)))
Discount Rate = 12.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.40%
[DCF Debug] Terminal Value 68.28% ; FCFE base≈156.9m ; Y1≈193.5m ; Y5≈330.2m
Fair Price DCF = 21.39 (DCF Value 2.91b / Shares Outstanding 135.8m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -3.36 | EPS CAGR: 10.87% | SUE: 0.10 | # QB: 0
Revenue Correlation: -9.36 | Revenue CAGR: 81.49% | SUE: 0.44 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.84 | Chg30d=-0.097 | Revisions Net=-1 | Analysts=6
EPS current Year (2026-09-30): EPS=-3.33 | Chg30d=-0.435 | Revisions Net=-5 | Growth EPS=-33163.6% | Growth Revenue=-53.1%
EPS next Year (2027-09-30): EPS=-4.55 | Chg30d=-0.748 | Revisions Net=+0 | Growth EPS=-36.8% | Growth Revenue=-26.3%
P/E Forward = 111.1111
P/S = 8.7844
P/B = 16.8169
P/EG = -1.32
Beta = 1.31
Revenue TTM = 829.4m USD
EBIT TTM = 83.1m USD
EBITDA TTM = 100.6m USD
Long Term Debt = 214.9m USD (from longTermDebt, last quarter)
Short Term Debt = 40.0m USD (from shortLongTermDebt, last quarter)
Debt = 111.4m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 166.2m USD (from netDebt column, last quarter)
Enterprise Value = 7.31b USD (7.29b + Debt 111.4m - CCE 88.7m)
Interest Coverage Ratio = 0.93 (Ebit TTM 83.1m / Interest Expense TTM 89.4m)
FCF Yield = 2.15% (FCF TTM 156.9m / Enterprise Value 7.31b)
FCF Margin = 18.91% (FCF TTM 156.9m / Revenue TTM 829.4m)
Net Margin = -0.20% (Net Income TTM -1.63m / Revenue TTM 829.4m)
Gross Margin = 97.89% ((Revenue TTM 829.4m - Cost of Revenue TTM 17.5m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 77.59%)
Tobins Q-Ratio = 5.28 (Enterprise Value 7.31b / Total Assets 1.39b)
Interest Expense / Debt = 19.47% (Interest Expense 21.7m / Debt 111.4m)
Taxrate = 55.37% (20.0m / 36.1m)
NOPAT = 37.1m (EBIT 83.1m * (1 - 55.37%))
Current Ratio = 4.86 (Total Current Assets 950.6m / Total Current Liabilities 195.5m)
Debt / Equity = 0.24 (Debt 111.4m / totalStockholderEquity, last quarter 466.1m)
Debt / EBITDA = 1.65 (Net Debt 166.2m / EBITDA 100.6m)
Debt / FCF = 1.06 (Net Debt 166.2m / FCF TTM 156.9m)
Total Stockholder Equity = 430.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.12% (Net Income -1.63m / Total Assets 1.39b)
RoE = -0.38% (Net Income TTM -1.63m / Total Stockholder Equity 430.4m)
RoCE = 12.87% (EBIT 83.1m / Capital Employed (Equity 430.4m + L.T.Debt 214.9m))
RoIC = 5.11% (NOPAT 37.1m / Invested Capital 725.7m)
WACC = 12.45% (E(7.29b)/V(7.40b) * Re(12.51%) + D(111.4m)/V(7.40b) * Rd(19.47%) * (1-Tc(0.55)))
Discount Rate = 12.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.40%
[DCF Debug] Terminal Value 68.28% ; FCFE base≈156.9m ; Y1≈193.5m ; Y5≈330.2m
Fair Price DCF = 21.39 (DCF Value 2.91b / Shares Outstanding 135.8m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -3.36 | EPS CAGR: 10.87% | SUE: 0.10 | # QB: 0
Revenue Correlation: -9.36 | Revenue CAGR: 81.49% | SUE: 0.44 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.84 | Chg30d=-0.097 | Revisions Net=-1 | Analysts=6
EPS current Year (2026-09-30): EPS=-3.33 | Chg30d=-0.435 | Revisions Net=-5 | Growth EPS=-33163.6% | Growth Revenue=-53.1%
EPS next Year (2027-09-30): EPS=-4.55 | Chg30d=-0.748 | Revisions Net=+0 | Growth EPS=-36.8% | Growth Revenue=-26.3%
Additional Sources for ARWR Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle